strategy. on morning, and Good us for continued joining recent open call. on on I you will execution our all Kate. and with progress thank comments Thanks, today's our
clinical Next, review for update our Anne-Marie available trials. questions. and be the for financials. on will Ginnie up And Chandra questions, X provide opening our ongoing before will an call Kyle will also
year marked steady by the execution been of has Wave. start The for
FORWARD-XX allele-selective towards and WVE-NXXX trial clinical with Exon which continued for patients RNA DMD; WVE-XXX, data SELECT-HD, we've potentially candidate with is our therapy HD. First, with WVE-XXX, for patients XX trials a This evaluating our key evaluating editing includes AATD; trial with advance ongoing X first-in-class, our RestorAATion amenable registrational underway, investigational our updates. boys our program, to clinical for
lead of year. as in of X a we for the they selected Last achievement first INHBE quarter following announced meaningful expect first candidate We towards year validation. target as our filing as next research this the our initiate their clinical GSK clinical obesity trial with of end early progress in CTA to and advance also continue to programs month, collaboration
each I'll exciting leadership an deeper update. pause program, to diving Before into acknowledge
As announced leveraging Erik In our Wave our platform strategy, our he genetics including multimodal Officer. will this emerging role, Chief to joined morning, RNA as Scientific Dr. therapeutic medicines. best-in-class drive high-impact has for new, capability novel advance and Ingelsson and targets portfolio this to continue growing identifying genomics
across genomics of responsible Professor to Sciences, comes is the methods development and novel Head most MD, and drug and Genomic where of us held Prior positions the SVP of of technologies of Ingelsson leading accelerate recently all Dr. medicines. activities University. from he areas. SVP, latest therapeutic He Discovery and at GSK, was PhD targets harnessing Stanford to Target in next-generation obtained Medicine and validate GSK, at to discover University he for
have to hear Erik will opportunity very the near in future. You the directly from
Turning to editing. in our RNA pipeline
mutant WVE-XXX is levels to of to wholly-owned clinical is editing trial and editing pipeline candidate, in mutation increase the to for of protein which antitrypsin continue now AATD AAT reduce AATD, Our it. we first liver. underway, deficiency, Z causing our RNA or RestorAATion-X behind advance circulating alpha-X wild-type clinical RNA the correct ever protein industry's and aggregation AAT aims WVE-XXX
solution standard-of-care The confined weekly a irreversible manifestations, or artificial often are injury. current and root Other treatment liver that lung enzymes address not on By to edits the both. treating editing exogenously designed exacerbate in XXX cause at hyperactive limited either and AATD lung lung technologies disease, collateral to AAT disease. development rely patients to could is treatments treating augmentation only disease only result DNA therapy differs indels. in bystander treatment is with disease lung RNA, delivered SiRNA IV both. confined of or XXX targeting from to that are can provide to liver liver approaches
variants. In events lower fact, to activity have the observed complex systems silencing yielded multiple in market. preclinical contains AAT highly WVE-XXX well studies, standard such that XXX tool and GalNAc-conjugate, create as were majority loss-of-function indels on with functional protein of LNPs. while does isoforms a the editing validated of the use using not the edits with DNA-based specific potential by is delivery elegant approved delivery that therapeutics
and is convenience dose the as high delivery organ. selective ease hepatocytes GalNAc since to and enables target the clinical effective degree translation to a as dosing, preclinical delivered confidence to of reliably well the of entire subcutaneous of
AAT chemistry neutrophil ADAR thresholds endogenous of Our populations, healthy the potent in and studies. achieve durable recruit we proprietary protein enables for shown preclinical levels the elastase confirm We've and exceed MZ MM functionality WVE-XXX enzymes with both this to that assay. and and the protein editing effectively
prevents increases improved in indicating hepatocytes Additionally, inflammation turnover aggregates. for liver we of of saw hepatocyte decreases mitosis also and lobular WVE-XXX of reduction survival.
will progress WVE-XXX our Anne-Marie in our of of make we received AATD year. from As proof first in continue trial later momentarily, significant with RestorAATion-X patients with for this to expected CTA speak data and to approval recently for RestorAATion-X mechanism
more substantial Their significant growing deep and RNA of would our both a genetic investments multimodal concept XXX broadly. to to mRNA correct they capability which candidates, Proof in the for makes recognize of development and XXX, mechanism continue derisk to medicine of commercialization also them differentiated meaningfully bring upregulate not their insights. for our either to an value through ideal partner in early at editing editing Wave respiratory serve GSK was rare leadership in our and for of AATD only potential prevalent as platform pipeline but or designed wholly-owned would are and program proof diseases.
of $XX into due to Development of million advancement first is a million The also the collaboration for eligible XXX $XXX tiered to study. GSK commercialization RestorAATion-X received to up included teens. clinic. in as royalties the of transferred Wave high sales milestones at sole the of related after cost quarter our net we responsibilities which to their double-digit the we complete and XXX, percentage
first selected programs the Wave. following marking a phase and of their collaboration Additionally, triggering to of collaboration, $XX the next to advance the research validation, X in transition payment million of target a the discovery GSK to part achievement
Wave's term. format these eligible total X programs initial RNA in including The Wave's [indiscernible] is component to utilize all modalities, of next-gen discovery and up hepatology. collaboration GalNAc-siRNA GSK Both the programs the of research during of encompasses to advance editing,
For Wave for of these collaboration potential sales. milestone billion royalties net to programs, on $X.X is total eligible as up as well payments X
and of our wholly-owned pipeline of related collaboration we The expands targets these GSK's reminder, GSK a cost are up measurable we best the target validated first-in-class also slots X Wave. INHBE programs biomarkers biology on our programs. targets pays advance in on As based novel remaining XXX% was we to partnered to focus potential. the as to to and leverage target plan genetics, for with strong able high-impact to first selected, clinical validation genetically
aims be to Our obesity next-generation INHBE therapeutic. a program
controls INHBE of to with silencing, function, protective fat including odds its or decreases diabetes mRNA phenotype and a recapitulate GalNAc-siRNA liver reduced fat heterozygous profile, abdominal is of we carriers, the Using loss which INHBE receptor reduced of X obesity, the in adipocytes, lipolysis burning on corresponding aim coronary fat INHBE have favorable expressed type accumulation. who cardiometabolic and promotes storage. artery Silencing disease.
standard come these several muscle high the poor care While GLP-Xs dosing, namely loss loss, limitations, with tolerability discontinuation of mass, frequent become for and rates. therapies have of weight
dose, obesity, INHBE market, on diet-induced milligram program, fat mass. with fat DIO, with The has clinic. every and intervals or no loss there With preferential is per a the And a silencing many mouse semaglutide supports an good including for which weight potent and for model. highly effect of been loss loss our than less potential used translation mass visceral or we kilogram annually. DIO into also demonstrated muscle following loss durable subcutaneous demonstrated with in precedent in X weight low months therapeutics X have with the weight the single-digit We've model reductions silencing EDXX X in of of dosing mouse the
an GLP-X, induction. also therapy we have distinct action is INHBE see of potentially opportunity effect loss mechanism or GLP-X use. frontline a And data observed was the single INHBE head-to-head preclinical to maintenance semaglutide. similar that further a loss this INHBE the now emerging mice, as use study to from we from the DIO weight As ongoing following in weight In support dose siRNA siRNA to we of our
addition, In of curtailed with upon semaglutide cessation expected treatment weight our treatment rebound INHBE gain. siRNA
year. siRNA from INHBE our to as INHBE be volunteers. can our believe trial in proof just the healthy to later file the a of this single remain to quarter share XXXX. study concept program in as of early clinical preclinical We our on expect initiate year and dose CTA of our clinical first achieved with the track We end data a overweight of new We of
to on we endogenous dystrophin FORWARD-XX trial clinical that benefit there to those to an therapeutic or is track need deliver potentially skipping. associated HD, deliver XX each with data especially to can to months. DMD more safety the Significant and is of In the registrational benefit and clinical on unknown the gene these urgent patients, functional in our in therapies goal gaps demonstrate our meaningful to in WVE-NXXX amenable of with to programs can an of clinical for heart and patients With coming access DMD, achieve and boys mini-dystrophin functional scientific AAV Exon we addition remain are which risk restore from provide to Becker-like micro- a diaphragm. options
distribution where we seen in including studies, areas substantial have our Two NHPs. preclinical
doses of NXXX the demonstration of the per We've stem and X nanograms for cells data muscle every best uptake XX,XXX half-life, concentrations supports tissue demonstrated clinical which it after Our potential monthly in exon-skipping dosing. industry-leading a other position clinical potentially for first only of class. gram, week, myogenic XX%, in as
trial strong on our XX-week make We to data the progress in expression in track quarter third dystrophin year. deliver continue to protein remain this and
at our mutant with function U.S. treatments in advance no HD. protein need huntingtin available, to which neurons. there while wild-type protein, to of HD are to continue therapeutic WVE-XXX. and health and the first-in-class patients reduce we of the huntingtin developing risk XX,XXX space disease-modifying XXX HD, HD of designed In this is patients high have also is unmet In as healthy approximately over sparing extremely XXX,XXX allele-selective critical
clear wild-type a lower this non-selectively the advantage is reserve. and as HD protein over ability with a important preserve that especially already start mutant to approaches wild-type patients PAM-silencing protein, Having lower
clinic first with clinical We of multi-dose trial looking huntingtin single and data in in and the mutant humans, data type wild to demonstrated we are compelling reduction of preclinical biomarker data replicate of the a SELECT-HD translation the second our our after these dose already have to successful from with preservation quarter.
the by enlargement. In addition, looking approaches, see if be to including closely can seen ventricular differentiate will on signals PAM-silencing we we safety
Now to on discuss turn Anne-Marie? Anne-Marie. the detail, progress over to in clinical like our more programs call made I'd to we've the
